Table 2.
Univariate analysis of overall survival
| Variables | n | mOS (month) | χ2 | P | |
|---|---|---|---|---|---|
| Age, y | ≥54/<54 | 41/39 | 26/20 | 1.405 | 0.236 |
| Gender | Male/Female | 75/5 | 26/11 | 16.305 | <0.001 |
| RT | A-RT/C-RT/Non-RT | 54/10/16 | 30/11/20 | 14.912 | 0.001 |
| A-RT/C-RT | 54/10 | 30/10 | 13.757 | <0.001 | |
| A-RT/Non-RT | 54/16 | 30/20 | 4.578 | 0.032 | |
| C-RT/Non-RT | 10/16 | 11/20 | 1.197 | 0.274 | |
| BED | ≥58.9 Gy/<58.9 Gy/0 Gy ≥58.9 Gy/<58.9 Gy ≥58.9 Gy/0 Gy <58.9 Gy/0 Gy |
42/22/16 42/22 42/16 22/16 |
42/19/20 42/19 42/20 19/20 |
5.763 3.890 4.740 0.048 |
0.016 0.049 0.029 0.827 |
| Types HBsAg Child Pugh classification |
I + II/III + IV Negative/Positive A/B |
12 + 28/18 + 22 23/57 50/30 |
42/31/19/17 30/21 31/18 |
8.757 0.392 12.682 |
0.003 0.531 <0.001 |
| PS (ECOG) Concomitant disease |
0–1/2–3 Yes/No |
59/21 62/18 |
31/11 23/29 |
30.943 0.567 |
<0.001 0.451 |
| Target therapy Center location |
Yes/No Right/Left |
30/50 60/20 |
24/23 23/21 |
0.202 0.223 |
0.653 0.637 |
| diameter, cm AFP, ng/L |
≥5/<5 ≤20/20 ~ 400/≥400 ≤20/20 ~ 400 ≤20/≥400 20 ~ 400/≥400 |
56/24 13/23/44 13/23 13/44 23/44 |
21/26 43/30/21 43/30 43/21 30/21 |
1.001 1.787 1.825 0.015 1.412 |
0.371 0.409 0.177 0.904 0.235 |
| PLT, 109/L HGB, g/L TBIL, μmol/L Albumin, g/L ALT, U/L AST, U/L |
≥100/<100 ≥120/<120 ≥20/<20 ≥35/<35 ≥50/<50 ≥50/<50 |
54/26 51/29 34/46 30/50 30/50 46/34 |
26/20 26/21 20/31 22/24 20/26 20/29 |
0.258 0.019 4.263 0.115 1.777 0.010 |
0.611 0.891 0.039 0.735 0.182 0.975 |
RT radiotherapy, A-RT accurate radiotherapy, 2D-RT two-dimensional radiotherapy, Non-RT non-radiotherapy, BED biologically effective dose, Types types of tumor thrombi, HBsAg hepatitis B surface antigen, PS performance status, ECOG Eastern Cooperative Oncology Group; Concomitant disease include hepatitis and hepatocirrhosis; Targeted therapy: sorafenib; AFP alpha–fetoprotein, PLT platelet, HGB Hemoglobin, TBIL total bilirubin, ALT alanine aminotransferase, AST aspartate aminotransferase, mOS median overall survival